Mesalamine Suppositories had US sales of approximately USD 263m for the 12 months ending March 2019, according to IMS Health.
Mesalamine Suppositories are indicated in adults for the treatment of mildly to moderately active ulcerative proctitis. The product should be taken only as prescribed.
Rising Pharmaceuticals, as the exclusive distributor for its development partner, Pharmaceutical Sourcing Partners, Inc., who recently received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application, will launch the product immediately.
Rising is a supplier of generic medicines in the US, and the launch of Mesalamine Suppositories, adds to the company's robust and expanding human pharmaceutical franchise.
Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers.
Currently, Rising has over 125 approved and commercial products in the US market and an additional 82 products pending launch or in development, representing a combined USD 12.5bn in addressable market value.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US